To Evaluate the Efficacy and Safety of JW0201 Added on in Patients With T2DM

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 196 participants.

Also called NCT05814406

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 196 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05814406
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05814406. Randomized; quadruple masking; primary purpose treatment. Start 2023-01-12 (actual); primary completion 2024-03-21 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
To Evaluate the Efficacy and Safety of JW0201 Added on in Patients With T2DM
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
JW0201
Intervention (Drug)
Placebo
Lead sponsor
JW Pharmaceutical (class: industry)

Record details

Record id
cardio:ct-nct05814406
Content hash
e7e3cb22465c99ad1222292dd3f7c595b42b0262fb878db1510e834b5a6ed09f